FDA Approves Bristol Myers Squibb’s Zenbexus, First CELMoD for Multiple Myeloma

Company: Bristol Myers Squibb · Event Type: Regulatory Approval · Product: Iberdomide (Zenbexus) · Mechanism: Cereblon E3 Ligase Modulator (CELMoD) · Indication: Multiple Myeloma (≥1 Prior Line) · Approval Date: August 14, 2026 Summary The FDA granted accelerated approval to Bristol Myers Squibb’s iberdomide (Zenbexus),…